Clinical Trial Update: Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in combination with TACE for hepatocellular carcinoma patients at high risk of post-surgical recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Hepatocellular Carcinoma, TACE | Phase 2 | Status: UNKNOWN